Decision trees to characterise the roles of permeability and solubility on the prediction of oral absorption

European Journal of Medicinal Chemistry

Volumn 90, Issue , 2015, Pages 751-765

  Newby, Danielle ^a   Freitas, Alex A ^b   Ghafourian, Taravat ^a,b  

^a MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Decision trees; Intestinal absorption; Permeability; QSAR; Solubility

Indexed keywords

CYTOCHROME P450 3A4; KETOCONAZOLE; MEBENDAZOLE; ZIPRASIDONE;

ARTICLE; DECISION TREE; DRUG ABSORPTION; DRUG SOLUBILITY; HUMAN; HYDROGEN BOND; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; MELTING POINT; ABSORPTION; ANIMAL; CACO 2 CELL LINE; DOG; MDCK CELL LINE; ORAL DRUG ADMINISTRATION; PERMEABILITY; SOLUBILITY;

ABSORPTION, PHYSIOLOGICAL; ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; DECISION TREES; DOGS; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; PERMEABILITY; SOLUBILITY;

EID: 84918836576     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.12.006     Document Type: Article

References (82)

1. D.A. Volpe, Variability in Caco-2 and MDCK cell-based intestinal permeability assays, J. Pharm. Sci. 97 (2008) 712-725.
2. A. Boobis, U. Gundert-Remy, P. Kremers, P. Macheras, O. Pelkonen, In silico prediction of ADME and pharmacokinetics - report of an expert meeting organised by COST B15, Eur. J. Pharm. Sci. 17 (2002) 183-193.
3. H. van de Waterbeemd, E. Gifford, ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2 (2003) 192-204.
4. G.L. Amidon, H. Lennernas, V.P. Shah, J.R. Crison, A theoretical basis for a biopharmaceutic drug classification - the correlation of in-vitro drug product dissolution and in-vivo bioavailability, Pharm. Res. 12 (1995) 413-420.
5. S.T. Buckley, S.M. Fischer, G. Fricker, M. Brandl, In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives, Eur. J. Pharm. Sci. 45 (2012) 235-250.
6. C.A. Lipinski, Drug-like properties and the causes of poor solubility and poor permeability, J. Pharmacol. Toxicol. Methods 44 (2000) 235-249.
7. J.M. Miller, A. Beig, B.J. Krieg, R.A. Carr, T.B. Borchardt, G.E. Amidon, G.L. Amidon, A. Dahan, The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation, Mol. Pharm. 8 (2011) 1848-1856.
8. V. Pade, S. Stavchansky, Link between drug absorption solubility and permeability measurements in Caco-2 cells, J. Pharm. Sci. 87 (1998) 1604-1607.
9. C.A.S. Bergstrom, M. Strafford, L. Lazorova, A. Avdeef, K. Luthman, P. Artursson, Absorption classification of oral drugs based on molecular surface properties, J. Med. Chem. 46 (2003) 558-570.
10. M.D. Wessel, P.C. Jurs, J.W. Tolan, S.M. Muskal, Prediction of human intestinal absorption of drug compounds from molecular structure, J. Chem. Inf. Comp. Sci. 38 (1998) 726-735.
11. T. Niwa, Using general regression and probabilistic neural networks to predict human intestinal absorption with topological descriptors derived from twodimensional chemical structures, J. Chem. Inf. Comp. Sci. 43 (2003) 113-119.
12. Y.H. Zhao, M.H. Abraham, J. Le, A. Hersey, C.N. Luscombe, G. Beck, B. Sherborne, I. Cooper, Rate-limited steps of human oral absorption and QSAR studies, Pharm. Res. 19 (2002) 1446-1457.
13. T.J. Hou, J.M. Wang, W. Zhang, X.J. Xu, ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification, J. Chem. Inf. Mod. 47 (2007) 208-218.
14. J.M. Wang, T.J. Hou, Recent advances on aqueous solubility prediction, Comb. Chem. High Throughput Screen. 14 (2011) 328-338.
15. T. Ghafourian, A.H.A. Bozorgi, Estimation of drug solubility in water, PEG 400 and their binary mixtures using the molecular structures of solutes, Eur. J. Pharm. Sci. 40 (2010) 430-440.
16. N. Jain, S.H. Yalkowsky, Estimation of the aqueous solubility I: application to organic nonelectrolytes, J. Pharm. Sci. 90 (2001) 234-252.
17. A.L. Cheng, K.M. Merz, Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships, J. Med. Chem. 46 (2003) 3572-3580.
18. X.Q. Chen, S.J. Cho, Y. Li, S. Venkatesh, Prediction of aqueous solubility of organic compounds using a quantitative structure-property relationship, J. Pharm. Sci. 91 (2002) 1838-1852.
19. J.B. Dressman, G.L. Amidon, D. Fleisher, Absorption potential: estimating the fraction absorbed for orally administered compounds, J. Pharm. Sci. 74 (1985) 588-589.
20. T. Sanghvi, N. Ni, S.H. Yalkowsky, A simple modified absorption potential, Pharm. Res. 18 (2001) 1794-1796.
21. K.A. Chu, S.H. Yalkowsky, An interesting relationship between drug absorption and melting point, Int. J. Pharm. 373 (2009) 24-40.
22. A. Braun, S. Hammerle, K. Suda, B. Rothen-Rutishauser, M. Gunthert, S.D. Kramer, H. Wunderli-Allenspach, Cell cultures as tools in biopharmacy, Eur. J. Pharm. Sci. 11 (2000) S51-S60.
23. P.V. Balimane, S.H. Chong, R.A. Morrison, Current methodologies used for evaluation of intestinal permeability and absorption, J. Pharmacol. Toxicol. Methods 44 (2000) 301-312.
24. J. Fogh, G. Trempe, Human tumor cells in vitro, in: J. Fogh (Ed.), Human Tumor Cells in Vitro, Plenum Press, New York, 1975, pp. 115-141.
25. I.J. Hidalgo, T.J. Raub, R.T. Borchardt, Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability, Gastroenterology 96 (1989) 736-739.
26. P. Artursson, Epithelial transport of drugs in cell-culture.1. A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells, J. Pharm. Sci. 79 (1990) 476-482.
27. M. Pinto, S. Robineleon, M.D. Appay, M. Kedinger, N. Triadou, E. Dussaulx, B. Lacroix, P. Simonassmann, K. Haffen, J. Fogh, A. Zweibaum, Enterocyte-like differentiation and polarization of the human-colon carcinoma cell-line caco- 2 in culture, Biol. Cell 47 (1983) 323-330.
28. R.B. van Breemen, L. Li, Caco-2 cell permeability assays to measure drug absorption, Expert Opin. Drug Metab. Toxicol. 1 (2005) 175-185.
29. M.J. Brisk-Anderson, J.W. Finley, S.M. Newman, The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells, Proc. Soc. Exp. Biol. Med. 214 (1997) 248-257.
30. E. Le Ferrec, C. Chesne, P. Artusson, D. Brayden, G. Fabre, P. Gires, F. Guillou, M. Rousset, W. Rubas, M.L. Scarino, In vitro models of the intestinal barrier e the report and recommendations of ECVAM Workshop 46, ATLA Altern. Lab. Anim. 29 (2001) 649-668.
31. P. Matsson, C.A.S. Bergstrom, N. Nagahara, S. Tavelin, U. Norinder, P. Artursson, Exploring the role of different drug transport routes in permeability screening, J. Med. Chem. 48 (2005) 604-613.
32. S. Tavelin, J. Taipalensuu, L. Soderberg, R. Morrison, S.H. Chong, P. Artursson, Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers, Pharm. Res. 20 (2003) 397-405.
33. C. Hilgendorf, H. Spahn-Langguth, C.G. Regardh, E. Lipka, G.L. Amidon, P. Langguth, Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport, J. Pharm. Sci. 89 (2000) 63-75.
34. J.D. Irvine, L. Takahashi, K. Lockhart, J. Cheong, J.W. Tolan, H.E. Selick, J.R. Grove, MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening, J. Pharm. Sci. 88 (1999) 28-33.
35. A. Avdeef, K.Y. Tam, How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? J. Med. Chem. 53 (2010) 3566-3584.
36. M.V. Varma, I. Gardner, S.J. Steyn, P. Nkansah, C.J. Rotter, C. Whitney-Pickett, H. Zhang, L. Di, M. Cram, K.S. Fenner, A.F. El-Kattan, pH-dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery, Mol. Pharm. 9 (2012) 1199-1212.
37. P. Artursson, J. Karlsson, Correlation between oral-drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells, Biochem. Biophys. Res. Commun. 175 (1991) 880-885.
38. P. Stenberg, U. Norinder, K. Luthman, P. Artursson, Experimental and computational screening models for the prediction of intestinal drug absorption, J. Med. Chem. 44 (2001) 1927-1937.
39. M.C. Gres, B. Julian, M. Bourrie, V. Meunier, C. Roques, M. Berger, X. Boulenc, Y. Berger, G. Fabre, Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line, Pharm. Res. 15 (1998) 726-733.
40. L. Di, C. Whitney-Pickett, J.P. Umland, H. Zhang, X. Zhang, D.F. Gebhard, Y.R. Lai, J.J. Federico, R.E. Davidson, R. Smith, E.L. Reyner, C. Lee, B. Feng, C. Rotter, M.V. Varma, S. Kempshall, K. Fenner, A.F. El-Kattan, T.E. Liston, M.D. Troutman, Development of a new permeability assay using low-efflux MDCKII cells, J. Pharm. Sci. 100 (2011) 4974-4985.
41. S.Y. Yee, In vitro permeability across Caco3 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth, Pharm. Res. 14 (1997) 763-766.
42. CDER/FDA, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, U.S. Department of Health and Human Services - Center for Drug Evaluation and Research. Guidance for Industry, 2000.
43. M.V.S. Varma, R.S. Obach, C. Rotter, H.R. Miller, G. Chang, S.J. Steyn, A. El-Kattan, M.D. Troutman, Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination, J. Med. Chem. 53 (2010) 1098-1108.
44. FDA, FDA Approved Drug Products Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (accessed from June 2012 to May 2013).
45. H.P. The, I. Gonzalez-Alvarez, M. Bermejo, V.M. Sanjuan, I. Centelles, T.M. Garrigues, M.A. Cabrera-Perez, In silico prediction of Caco-2 cell permeability by a classification QSAR approach, Mol. Inf. 30 (2011) 376-385.
46. M.V.S. Varma, K. Sateesh, R. Panchagnula, Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport, Mol. Pharm. 2 (2005) 12-21.
47. K. Sugano, M. Kansy, P. Artursson, A. Avdeef, S. Bendels, L. Di, G.F. Ecker, B. Faller, H. Fischer, G. Gerebtzoff, H. Lennernaes, F. Senner, Coexistence of passive and carrier-mediated processes in drug transport, Nat. Rev. Drug Discov. 9 (2010) 597-614.
48. BNF, British National Formulary, September 64 ed., BMJ Group and Pharmaceutical Press, London, 2012.
49. Martindale the Complete Drug Reference, 36 ed., Pharmaceutical Press, London, 2009.
50. L. Breiman, J. Friedman, C.J. Stone, R.A. Olshen, Classification and Regression Trees, first ed., Chapman and Hall/CRC, Boca Raton, 1984.
51. D. Newby, A.A. Freitas, T. Ghafourian, Coping with unbalanced class data sets in oral absorption models, J. Chem. Inf. Mod. 53 (2013) 461-474.
52. G.J. Hahn, Fitting regression models with no intercept term, J. Qual. Technol. 9 (1977) 56-61.
53. D. Newby, A.A. Freitas, T. Ghafourian, Pre-processing feature selection for improved C&RT models for oral absorption, J. Chem. Inf. Mod. 53 (2013) 2730-2742.
54. Z. Gao, Development of a continuous dissolution/absorption system-a technical note, AAPS Pharm Sci Tech 13 (2012) 1287-1292.
55. A. Mehramizi, B. Alijani, M. Pourfarzib, F.A. Dorkoosh, M. Rafiee - Tehrani, Solid carriers for improved solubility of glipizide in osmotically controlled oral drug delivery system, Drug. Dev. Ind. Pharm. 33 (2007) 812-823.
56. G. Englund, F. Rorsman, A. Ronnblom, U. Karlbom, L. Lazorova, J. Grasjo, A. Kindmark, P. Artursson, Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells, Eur. J. Pharm. Sci. 29 (2006) 269-277.
57. A.-L.B. Ungell, Caco-2 replace or refine? Drug. Discov. Today: Technol. 1 (2004) 423-430.
58. C. Hilgendorf, G. Ahlin, A. Seithel, P. Artursson, A.L. Ungell, J. Karlsson, Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines, Drug Metab. Dispos. 35 (2007) 1333-1340.
59. R. Hayeshi, C. Hilgendorf, P. Artursson, P. Augustijns, B. Brodin, P. Dehertogh, K. Fisher, L. Fossati, E. Hovenkamp, T. Korjamo, C. Masungi, N. Maubon, R. Mols, A. Mullertz, J. Monkkonen, C. O'Driscoll, H.M. Oppers-Tiemissen, E.G.E. Ragnarsson, M. Rooseboom, A.L. Ungell, Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories, Eur. J. Pharm. Sci. 35 (2008) 383-396.
60. Y. Quan, Y. Jin, T.N. Faria, C.A. Tilford, A. He, D.A. Wall, R.L. Smith, B.S. Vig, Expression profile of drug and nutrient absorption related genes in Madin-Darby canine kidney (MDCK) cells grown under differentiation conditions, Pharmaceutics 4 (2012) 314-333.
61. P. Shah, V. Jogani, T. Bagchi, A. Misra, Role of Caco-2 cell monolayers in prediction of intestinal drug absorption, Biotechnol. Progr. 22 (2006) 186-198.
62. H. Pham-The, I. González-Álvarez, M. Bermejo, T. Garrigues, H. Le-Thi-Thu, M.Á. Cabrera-Pérez, The use of rule-based and QSPR approaches in ADME profiling: a case study on Caco-2 permeability, Mol. Inf. 32 (2013) 459-479.
63. S. Shugarts, L.Z. Benet, The role of transporters in the pharmacokinetics of orally administered drugs, Pharm. Res. 26 (2009) 2039-2054.
64. G. Minuesa, C. Volk, M. Molina-Arcas, V. Gorboulev, I. Erkizia, P. Arndt, B. Clotet, M. Pastor-Anglada, H. Koepsell, J. Martinez-Picado, Transport of lamivudine (-)-beta-L-2′,3′-dideoxy-3′-thiacytidine and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3, J. Pharmacol. Exp. Ther. 329 (2009) 1187.
65. M.F. Hebert, Contributions of hepatic and intestinal metabolism and Pglycoprotein to cyclosporine and tacrolimus oral drug delivery, Adv. Drug Deliv. Rev. 27 (1997) 201-214.
66. W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, K. Baner, L.Z. Benet, K.F. Sewing, U. Christians, Small intestinal metabolism of the 3-hydroxy-3-methylglutary-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin, J. Pharmacol. Exp. Ther. 291 (1999) 131-139.
67. M. Gertz, A. Harrison, J.B. Houston, A. Galetin, Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data, Drug Metab. Dispos. 38 (2010) 1147-1158.
68. U. Fagerholm, Prediction of human pharmacokinetics - gut-wall metabolism, J. Pharm. Pharmacol. 59 (2007) 1335-1343.
69. J.H. Lin, M. Chiba, T.A. Baillie, Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev. 51 (1999) 135-157.
70. D.E. Clark, Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption, J. Pharm. Sci. 88 (1999) 807-814.
71. C.A. Bergstrom, In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption, Basic Clin. Pharmacol. Toxicol. 96 (2005) 156-161.
72. A.T. Balaban, Highly discriminating distance-based topological index, Chem. Phys. Lett. 89 (1982) 399-404.
73. J. Gasteiger, M. Marsili, Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges, Tetrahedron 36 (1980) 3219-3228.
74. G. Merino, A.I. Alvarez, M.M. Pulido, A.J. Molina, A.H. Schinkel, J.G. Prieto, Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion, Drug Metab. Dispos. 34 (2006) 690-695.
75. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 23 (1997) 3-25.
76. K.T. Savjani, A.K. Gajjar, J.K. Savjani, Drug solubility: importance and enhancement techniques, ISRN Pharm. (2012) 1-10. Article ID 195727.
77. K. Sugano, Fraction of a dose absorbed estimation for structurally diverse low solubility compounds, Int. J. Pharm. 405 (2011) 79-89.
78. S. Stegemann, F. Leveiller, D. Franchi, H. de Jong, H. Linden, When poor solubility becomes an issue: from early stage to proof of concept, Eur. J. Pharm. Sci. 31 (2007) 249-261.
79. J.P.F. Bai, A. Utis, G. Crippen, H.D. He, V. Fischer, R. Tullman, H.Q. Yin, C.P. Hsu, L. Jiang, K.K. Hwang, Use of classification regression tree in predicting oral absorption in humans, J. Chem. Inf. Comp. Sci. 44 (2004) 2061-2069.
80. W.J. Egan, K.M. Merz, J.J. Baldwin, Prediction of drug absorption using multivariate statistics, J. Med. Chem. 43 (2000) 3867-3877.
81. Y.H. Zhao, J. Le, M.H. Abraham, A. Hersey, P.J. Eddershaw, C.N. Luscombe, D. Boutina, G. Beck, B. Sherborne, I. Cooper, J.A. Platts, Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors, J. Pharm. Sci. 90 (2001) 749-784.
82. H. Pham-The, T. Garrigues, M. Bermejo, I. González-Álvarez, M.C. Monteagudo, M.Á. Cabrera-Pérez, Provisional classification and in silico study of biopharmaceutical system based on Caco-2 cell permeability and dose number, Mol. Pharm. 10 (2013) 2445-2461.